Roche CFO: Deal's on track

roche building

Roche may have soothed investors and placated Genentech folks with an announcement yesterday, but its own workforce could understandably be quaking in its collective boots.

Here's the story: At the J.P. Morgan Healthcare Conference, Roche CFO Erich Hunziker contended that "Everything is absolutely going on exactly as planned" with the Genentech deal, the San Francisco Chronicle reports. And while acknowledging that the financing environment is "very complex and "not very stable" at present, he appeared undaunted. "I think I don't look worn out. And I don't look pessimistic."

Okay, the deal's still considered a go, whether at a higher price as the Financial Times has reported (Hunziker wouldn't comment on that) or as previously offered. Hunziker also spoke to Genentech's future should Roche take over completely: The Swiss drugmaker would make Genentech one of its three main research centers, and Genentech would continue to have "a very high level of autonomy." Roche sees that Genentech's beauty lies in its innovative culture, and it doesn't want to "kill the hens that laid the golden eggs."

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

So the Genentech folks might say whew! But along with those assurances of autonomy came this zinger for Roche's own: Any staff cuts would be "much tougher" at Roche than they would at Genentech if the company decides to scale down. How many Roche-ians are now updating their resumes?

- see the Chronicle story
- read the story at BNet


Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

In its quest to become the dominant SGLT2 diabetes med for heart failure, Jardiance is touting DPP-4 inhibitor-topping data to support its case.

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.